Nomination of Arne Ferstad as new board member of Peptonic Medical

Stockholm 7th July 2016. - Peptonic Medical AB (publ) ("the Company" or "Peptonic") – a company developing pharmaceuticals based on oxytocin  - today announces that the Board, supported by the largest shareholders, will propose to the Extraordinary General Meeting on July 22th, that Mr Arne Ferstad be elected as new non-executive Board Member of Peptonic Medical.

Prof. Emeritus Andris Kreichbergs has announced that he wants to resign from the Board for personal reasons.

For more information, please contact;
Johan Inborr, CEO
Telephone: 　+46　708　853　893

E-mail:

johan.inborr@peptonicmedical.se 

About Arne Ferstad

Arne Ferstad has broad experience of the medical device, biotech and pharmaceutical industries, including General Management, R&D, Business Development and International Marketing and Sales. He has been in charge of Baxter Healthcare’s business in the Nordic and Benelux countries, served as President of EMEA Baxter Renal Division, managed Baxter’s bioscience business in Asia and has held several senior positions within Baxter Healthcare Inc. in the USA. He has also worked as Subsidiary CEO/General Manager and VP at Pharmacia Corporation. 　Arne Ferstad is presently Chairman and CEO of Ankor Consultants Ltd, where he works with clients as consultant, as interim executive and non-executive board member of several companies. Education in finance, marketing and completed the CEDEP, Executive Management Program at INSEAD Cedep, France.

Other current assignments:　

CEO and chair of Ankor Consultants Ltd (United Kingdom), Board member and Chairman of the board in Aggancio Research AB and CombiGene AB. Board member of NeuroVive Pharmaceutical AB, Clinical Laserthermia Systems AB and C G VET AB

About Peptonic Medical

Peptonic  Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Peptonic Medical’s mission is to develop safe and effective drugs based on the well-known beneficial properties of oxytocin.